Hepatitis/MASH

California's Affordable Care Act health insurance exchange marketplace is the first in the nation to enact a payment cap policy for expensive specialty drugs.

Preventative measures emphasized to reduce transmission of disease.

Early research in HIV and hepatitis B discontinued.

Gaining approval from insurance companies for highly effective new hepatitis C virus treatments is fraught with challenges for patients.

Advocacy group staffed by hepatitis C patients helps others find hope in fight against the disease.

New hepatitis C drugs moved the dream of a cure into a reality that gives patients a new chance at life.

Hyperlipidemia found to alter immune response.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.

Infants whose mothers were treated with telbivudine while pregnant were HBV-negative at 6 months after birth.

Here are new drugs for 2015 pharmacists can expect to handle.

The total cost of health must be considered in light of a potential cure.

High costs associated with new chronic hepatitis C virus (HCV) treatments should prompt pharmacists to reconsider their formula for determining the drugs' worth.

Agency notes that expedited approvals do not compromise quality standards.

Researchers find cooperation among viral variants that help hepatitis C to survive.

Comprehensive screening guidelines needed for populations with multiple risk factors.

Marketplace users less likely to use most medication classes except for hepatitis C and HIV.

Therapy is also being evaluated for advanced chronic kidney disease, inherited blood disorders, and liver cirrhosis.

Predictive model uses routine lab values and machine learning method.

Merck is seeking FDA approval for its once-daily, single-tablet grazoprevir/elbasvir combination for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 4, or 6 infection.

Combination is now being considered for patients who received a liver transplant.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.

The FDA today amended its breakthrough therapy designation for an experimental hepatitis C drug combination.

Study finds benefits from reduced absenteeism and improved workplace productivity.

Height can impact wait times for transplantation and overall mortality.

Blood test predicts which patients will respond to interferon.

Promising results from generic formulation of drug used post-transplant to reduce the risk of organ rejection.

Investigational 3-drug combination cleared the virus in 93% of treatment-naïve patients.

Direct-acting-antiviral drugs daclatasvir, asunaprevir, and beclabuvir showed high rates of sustained virologic response after 12 weeks.

Study finds chronic hepatitis C has a limited impact on mortality unless the patient has other severe comorbidities.

HIV and HCV co-infected patients with HALS found to be more likely to develop cirrhosis.